Hepatic encephalopathy and the gamma-aminobutyric-acid neurotransmitter system. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. 134(5):1352-9.Įsrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Martin-Llahi M, Pepin MN, Guevara M, et al.
MELD SCORE OF 17 TRIAL
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis. 29(10):1196-211.Īppenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. Emergent stent occlusion for TIPS-induced liver failure. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Salerno F, Camma C, Enea M, Rossle M, Wong F. The North American study for the treatment of refractory ascites. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Compensated cirrhosis: natural history and prognostic factors. Optimization of ascitic fluid culture technique. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. A randomized controlled study of 100 patients. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. Runyon BA, McHutchison JG, Antillon MR, et al. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Ascites and spontaneous bacterial peritonitis. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Runyon BA, Montano AA, Akriviadis EA, et al. Baroreceptor sensitivity and baroreceptor effectiveness index in cirrhosis: the relevance of hepatic venous pressure gradient. Genovesi S, Prata Pizzala DM, Pozzi M, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases.
:strip_exif()/i/2002842400.jpeg "meld score of 17")
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. 371-85.ĭirchwolf M, Podhorzer A, Marino M, et al. Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Arab JP, Dirchwolf M, Alvares-da-Silva MR, et al. Current treatment paradigms and emerging therapies for NAFLD/NASH. Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Van De Wier B, Koek GH, Bast A, Haenen GR. Does weight history affect fibrosis in the setting of chronic liver disease?. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Centers for Disease Control and Prevention. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
0 kommentar(er)
